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Genetic association of Canine Lymphocytic Thyroiditis 







 Canine Lymphocytic Thyroiditis (CLT) resembles naturally occurring lymphocytic 
thyroiditis in White Leghorn chickens and Hashimoto's thyroiditis in man. It is a 
common autoimmune endocrine disease in dogs which is a result of destruction of the 
thyroid glands. Many autoimmune diseases show associations with the major 
histocompability complex (MHC) class II alleles.  
 Within the canine Major Histocompatibility Complex (DLA) some of the class II 
genes are highly polymorphic. In this study an evaluation of the association between 
DLA class II haplotype and the risk for developing CLT has been performed by 
sequencing the polymorphic exon 2 form the genes DLA-DRB1, DLA-DQA1 and 
DQB1.  
 Two high-risk breeds for developing CLT, Giant Schnauzer and Hovawart, have been 
analysed from a total of 198 dogs. Included in the study were 35 healthy controls, 3 
borderline cases and 87 CLT-positive dogs.  
 Results show that Giant Schnauzers carrying the haplotype 
DRB1*01201DQA1*00101DQB1*0020 have an increased risk to develop CLT, cases 
22.5% versus controls 4.5%.  
This with an odds ratio = 6.0667 and with a p value = 0.015401 which shows that the 
increased risk to develop CLT is statistically significant.  
In Hovawart dogs the risk haplotype 01201*00401*013017 was present in 45 % 
(cases 43% versus controls 50%) of the total dogs analyzed. In this breed there was no 


























2.2 Canine Lymphocytic Thyroiditis……………………………………….4 




2.3 MHC class II………………………………………………………….....  5 
 2.4. Giant Schnauzer and Hovawart as model breeds……………………. 6 
3. Material and methods…………………………………………………...7  
3.1. Study material…………………………………………………………...7 
3.2. Clinical diagnosis………………………………………………………..7 
3.3. Extraction of genomic DNA.……………………………………………7 
3.4. PCR amplification……………….……………………………………...7 
3.5. Sequencing……………………………………………………………….8 
3.6. Data analysis……………………………………………………………..8 
3.7. Statistical analysis…………………………………………………….…8 
4. Results…………………………………………………………………….....9 
4.1. Clinical diagnosis…………………………………………………....…...9 
4.2. Data analysis………………………………………………………...…...9 




8. Supplementary tables……………………………………………..…....16 
8.1. Table S1. Clinical and diagnostic information for all dogs…….……16 
8.2. Table S2A. Giant Schnauzer 2x2 Contingency tables..…………...….21 

















CLT  Canine lymphocytic thyroiditis 
CTLA4 Cytotoxic T lymphocyte-associated 4 
DLA  Dog leukocyte antigen 
GS   Giant Schnauzer   
GWA  Genome-wide Association  
HLA  Human leukocyte antigen  
HW  Hovawart 
LYP  Lymphoid tyrosine phosphatase  
MHC               Major Histocompatibility Complex 
T3  Thyronin  
T4  Thyroxin  
TgAA  Thyroglobulin autoantibody 



































 The major histocompatibility complex (MHC) class II genes are strong genetic risk 
factors for many autoimmune diseases including Lymphocytic Thyroiditis in canines. 
Two dog breeds, Giant Schnauzer (GS) and Hovawart (HW), which shows an 
increased risk for developing the disease, were included in the study.  
 A genetic association between canine lymphocytic thyroiditis (CLT) and the DLA-
DRB1*01201 allele has already showed to be an increased risk factor.1 
 The aims of this study is to extend the DLA-DRB1 study by also determine the 
nucleotide sequence of the polymorphic exon 2  for DLA-DQA1 and –DQB1 genes 
and then evaluate whether there is an association between DLA class II haplotype and 
the risk for developing CLT. 
 
2.1 Autoimmunity 
 The immune system’s task is to protect the body against foreign organisms and 
material. Therefore it is essential to know what is self (autoantigen) and what is 
foreign (non-self) to the body. Autoimmunity is the failure of an organism to 
completely recognize what is self and what is foreign to the body. This results in an 
immune response against its own cells and /or tissue.2 
 Most immunodeficiency diseases results from a defective gene which results in an 
elimination or mutation in one or more components in the immune system. This can 
effect T- or B-lymphocyte development, phagocyte function and components of the 
complement system.  
 Self tolerance is normally controlling and preventing autoimmune diseases.3 During 
development, self and non-self antigens are presented by MHC class I and II 
molecules to T-lymphocytes. Those T-cells that interact get a protective signal that 
prevents apoptosis. Those that have not reacted with MHC go through cell death. This 
process is known as positive selection. During negative selection, the surviving 
thymocytes are tested for affinity for MHC molecules on antigen presenting cells. 
Only those with a low to moderate affinity are able to mature.4 
 Despite this process, some self-reacting lymphocytes do mature and can be activated 
and cause autoimmune diseases, also not all self antigens are expressed during 
development.3  
 Autoimmune diseases can be classified into two types, organ-specific or systemic. In 
organ-specific autoimmune diseases the autoimmunity is only expressed in a certain 
organ compared to systemic, where many tissues in the body are affected.  Table 1a 
and b shows organ-specific and systemic autoimmune diseases in humans and which 
autoantigen that is recognized.2   
 
Table 1a. Organ-specific autoimmune diseases in humans.2  
Autoantigen Disease Target organ  
TSH receptors (hGT) 
Thyroid peroxidise 
Myelin sheets 





Type 1 diabetes mellitus 
Thyroid glands 
Thyroid glands 







Table 1b. Systemic autoimmune diseases in humans.2   
Autoantigen Disease   
Joints, skin, blood vessels, 
heart, lungs and muscles  
Cells in skin, kidney and 
brain 
Skin and intestine 







Sjögren's syndrome  
  
 
 Autoimmune diseases are a result of multiple factors, both genetic and 
environmental.  
Most of the genes that are predisposing factors affect autoantigen availability, 
apoptosis, signalling pathways, cytokine expression and expression of co-stimulatory 
molecules.3 
 
2.2. Canine Lymphocytic Thyroiditis 
 Canine hypothyroidism is a common endocrine disease of dogs and approximately 
half of all cases are caused by lymphocytic thyroiditis, which is similar to 
Hashimoto’s thyroiditis in man and lymphocytic thyroiditis in White Leghorn 
chickens. The disease is characterized by an increase of infiltration of autoreactive T 
cells and other activated lymphocytes in the thyroid gland, autoantibodies against 
proteins from the thyroid gland and high concentrations of thyroid stimulating 
hormones (TSH).5  
2.2.1. Hypothyroidism  
 Hypothyroidism is a result of destruction of the thyroid gland. The thyroid gland is 
located in the neck, above the larynx and its main function is to produce thyroxin (T4) 
that regulates the metabolism. If the T4 levels in the blood are too low the pituitary 
glands is stimulated to produce TSH by hypothalamus that produces TRH.6 Secretion 
of TSH stimulates secretion of T4 and triiodothyronine (T3). When the T4 and T3 
levels increase the TSH secretion is inhibited by negative feedback.7 See Figure 1.  
 
 
Figure 1. Regulation of thyroid hormones through a negative feedback mechanism8 
(Cargill. J. et al. 2005. Hypothyroidism article).  
 
  The physiology of thyroid glands is the basics for all tests for hypothyroidism. The 
cause of hypothyroidism can be classified as primary, secondary or tertiary. At the 
primary causes, the levels of T4 and T3 are low but the TSH secretion is increased 
which is associated with the thyroid glands. Secondary causes are associated with a 
deficiency of TSH and pituitary glands and tertiary causes with a TRH deficiency 
from hypothalamus. CLT is an autoimmune disease that is associated with the primary 
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causes where the thyroid glands are infiltrated with lymphocytes that destroy the 
thyroid cells that produce T4. Therefore a large amount of free T4 is circulating in the 
bloodstream and also an increase of TSH can be shown. 6 
2.2.2. Symptoms 
 The thyroid gland regulates the cell metabolism. The hormones produced by the 
thyroid glands are necessary for embryonic development, stimulate protein and 
enzyme synthesis and also protein and fat metabolism. Therefore, a dysfunction in the 
thyroid glands produces a wide range of different symptoms. More than 75 % of the 
thyroid glands need to be destroyed to develop symptoms. Since the cellular 
metabolism is decreasing with an absence of thyroid hormones the first symptoms can 
be tiredness and inactivity. Also reproduction and the central nervous system can be 
affected. A weight gain, depression, weakness and freezing are other clinical sign of a 
decrease in metabolism. Dermatological changes can also be observed. The fur 
becomes dry or fat and oily.9 
2.2.3. Clinical diagnosis 
 Diagnosis requires laboratory testing where the T4 and TSH assays provide the most 
accurate information. Both increases in the T4 levels and TSH provide good evidence 
for CLT. Amount of T3 is not by itself a good indicator because the secretion does not 
decrease significant. Thyroglobulin autoantibodies (TgAA) occur frequently in dogs 
diseased with CLT. Therefore analysis for the presence of these autoantibodies is also 
performed during clinical diagnosis.7 
 
2.3. MHC class II  
 In humans, three gene regions have shown to be particularly involved in autoimmune 
diseases: The human leukocyte antigen (HLA) class II region, the gene encoding 
cytotoxic T lymphocyte-associated 4 (CTLA4) and the gene encoding lymphoid 
tyrosine phosphatase (LYP).10 Among these, most autoimmune diseases show 
associations with MHC class II alleles. This is not surprising since autoimmune 
responses involve the ability for T cells to recognise a particular antigen and this is 
dependent on the MHC genotype.3 
 The HLA class II region is a part of the MHC and is located on chromosome 6p21. 
Alleles and haplotypes of DQB1, DQA1 and DRB1 have shown to either predispose or 
protect for many autoimmune diseases.10  
 Hashimoto’s thyroiditis shows an association with the HLA-DR5 haplotype with a 
relative risk of 3.2.3 Because of that it is interesting to also study this gene in dogs 
diseased with CLT. 
 The canine Major Histocompatibility Complex (DLA) is located on chromosome 12 
and can as in other mammalian species be divided into class 1, 2 and 3 regions. The 
structures of DLA class II genes are similar to humans. The DLA region contains one 
functional gene at each locus i.e. DQA1, DQB1 and DRB1 (which are orthologs to 
human). The DQB1, DQA1 and DRB1 loci are in high linkage disequilibrium and 
haplotypes can therefore be used as genetic risk factors. DQA1 and DQB1 are located 
very close to each other and in complete LD and recombination between them has 
never been observed.  
 Within the DLA class II complexes, the genes are highly polymorphic. The latest 





2.4. Giant Schnauzer and Hovawart as model breeds 
 The domestic dog, Canis familiaris, is an excellent model species having over 400 
recognized breeds in which to study complex inherited diseases. These breeds are 
phenotypically diverse and each represents a closed breeding population. Several 
autoimmune diseases exist in dogs and can be compared to humans in both symptoms 
and inheritance. This is due to the genetic bottleneck caused by breed creation.13 
 A higher incidence for hypothyroid diseases have been reported  for Dobermans, 
Great Danes, Irish Setter , Miniature Schnauzer , Boxers, Golden Retrievers, 
Dachshunds, Shetlands Sheepdogs, Pomeranians, Cocker Spaniel and Airedale 
Terriers14. Giant Schnauzer and Hovawart are two dog breeds that previously not have 
been reported as being high risk breeds. The overall prevalence in the Swedish GS 






























3. Material and methods 
 
3.1. Study material  
 Blood samples from two high-risk breeds Giant Schnauzer and Hovawart are 
available from the registry at the Swedish Kennel Club. Two birth cohorts (1992 and 
1995) at 7-8 and 4-5 years of age, respectively, were collected and analysed. Clinical 
and diagnostic information is available for 198 dogs and is summarized in 
supplementary Table S1. A total of 35 controls (GS=22; HW=13), 3 borderline cases 
(GS=3; HW=0) and 87 CLT-positive cases (GS=58; HW=29) were included in the 
study.  
 
3.2. Clinical diagnosis 
 Each dog in the study was classified by strict inclusion and exclusion criteria.  
TSH levels above 29mgU/l and TgAA concentration at ≥150% compared to a 
negative control serum were used as inclusion criteria. Exclusion criteria were TSH 
levels below 20mgU/l and TgAA concentration below 100% compared to a negative 
control serum. Borderline cases were dogs with TSH levels between 20-29mgU/l and 
TgAA concentration between 100-150% compared to a negative control serum.  
 
3.3. Extraction of genomic DNA 
 Genomic DNA was extracted from 200 μl blood using a salt extraction method. The 
concentration and quality of the DNA were measured by NanoDrop ND-1000 
spectrophotometer 3.1.0.  
 
3.4. PCR amplification 
 PCR was performed according to protocol developed by Lorna Kennedy, Manchester 
University. PCR reactions was performed using 20ng DNA in a 20µl reaction 
containing 1x PCR buffer as supplied by Qiagen (with no extra Mg2+), Q solution 
(Qiagen), final concentrations of 0.1µM for each primer, 200µM each dNTP, with 2 
units of Taq polymerase, (Qiagen HotStarTaq). For primers used to amplify DLA-
DRB1, DQA1 and DQB1 respectively, see table 2. All primers are intronic and locus 
specific.  Both M13 and T7 tailed primers were used for labelling the PCR products. 
Better results were generated for DQA1 with tailed M13 primers and for DRB1 and 
DQB1 with T7.  
 
Table 2. Primers used to sequence DLA-DRB1, DQA1 and DQB1. (10) 
Primer  Primer sequence 5’-3’ Product 
size 
 









(T7)TGT GTC ACA CAC CTC AGC ACC A 
 
GGA CAG ATT CAG TGA AGA GA 
 
(T7)CTC ACT GGC CCG GCT GTC TC 
 
 
TAA TAC GAC TCA CTA TAG GG 
TGT AAA ACG ACG GCC AGT15 
303 bp  
 
345 bp  
 




 A standard Touchdown PCR protocol was used for all amplifications, which 
consisted of an initial 15 minutes at 95°C, 14 touch down cycles of 95°C for 30 
seconds, followed by 1 minute annealing, starting at 62°C (DRB1), 54°C (DQA1) 
73°C (DQB1) and reducing by 0.5°C each cycle, and 72°C for 1 minute. Then 20 
cycles of 95°C for 30 seconds, 55°C (DRB1), 47°C (DQA1) 66°C (DQB1) for 1 
minute, 72°C for 1 minute plus a final extension at 72°C for 10 minutes.  
 
3.5. Nucleotide sequence analysis 
 Sequencing was performed by Lark Technologies DNA sequencing services (LARK, 
Texas and England). Sequencing was only made in one direction, reverse for DRB1 
and DQA1 and forward for DQB1. 
 
3.6. Data analysis 
 The sequence data were analyzed by using the Macintosh software, MatchTools and 
MatchToolsNavigator (AppliedBiosystems, CA, USA), also used for assigning the 
alleles. The sequences were firstly read in the program MatchToolsNavigator and 
compared to an already prepared consensus sequence.12 Each polymorphic site was 
viewed and manually examined. When the sequence had been corrected, the sequence 
was put in the program MatchTools. A reference sequence library was already 
created6 and used to compare obtained sequence data with. MatchTools then provides 
a report of the closest matching allele.  
 
3.7. Statistical analysis 
 Statistical analyses were performed using VassarStats16 using a 2x2 Contingency 
Table to investigate if the results were statistically significant. Cases and controls 
were divided into presence or absence of the allele and the total number of individuals 
in each group was calculated. Then a comparison was made to the total number of 
alleles in each group. Odds Ratios (OR), Relative Risk (RR) and p-values were 
calculated for each haplotype in both Giant Schnauzer and Hovawart. Both the odds 
ratio and the relative risk compare the likelihood of an event between two groups. The 
estimation of the RR can be calculated using the formula: 
RR = (a/c)*k / (b/d)*k = (a/c)/(b/d) = ad/bc 
A RR close to 1 implies no risk for those who are carrying the allele to develop the 
disease. RR values above 1 show an increased risk and below 1 a lower risk for 
developing the disease. A stronger association is seen the further away from 1 the 
number is calculated. To determine if the association is significant p-values are 
calculated. A p-value < 0.05 shows statistical significance.  
 For the χ2 test Yates continuity correction values were used. χ2 tests are performed to 










4.1. Clinical diagnosis 
 Diagnostic criteria of all available samples are found in Table 3 and supplementary 
Table S1.   
 




4.2. Data analysis 
 Supplementary Table S1 shows all haplotypes generated. Table 4A shows the 
haplotype frequency for cases and controls in Giant Schnauzer and table 4B in 
Hovawart. The 01201*00101*00201 haplotype shows an increased risk (cases 22.5% 
versus controls 4.5%) for Giant Schnauzer to develop CLT.  
 


















00101*00101*00201 28 26 32 
00601*00401*01303 11.5 8.5 18 
00901*00101*008011 1.5 0 4.5 
01201*00101*00201 17.5 22.5 4.5 
01301*00101*00201 8 9.5 4.5 
01301*00301*00501 22.5 24 18 
02301*00301*00501 9.5 7 16 
09401*00401*01303 0 0 0 
09501*00101*00201 0 0 0 




Diagnostic criteria Presented 
samples  
Status 
1 TgAA≥199 and TSH ≥39 14 Case 
2 TgAA≥199 19 Case 
3 TSH≥39 23 Case 
4 CLT diagnosed and under treatment 9 Case 
5 200>TgAA>149 and 40>TSH> 29 0 Case 
6 200>TgAA> 149 14 Case 
7 40>TSH> 29 8 Case 
8 TSH<20, TgAA<100, T4 5-25, age 
>8years when analysed 
28 Control 
9 TSH<20, TgAA<100, T4 5-25,  
exact age not available 
7 Control 
10 150>TgAA> 100 and 29>TSH> 20 3 Borderline case 
? Can not be classified 73 - 
Blank Values are missing 6 - 
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00201*00901*00101 19  24  7.5  
01101*00201*01302  6  3.5  11.5 
01201*00401*013017  45   43   50 
01301*00101*00201  13   15.5  7.5  
01301*00101*00802 1  0  4  
01501*00601*00301  6  5   7.5  
01501*00601*04901  1  0  4  
01501*00601*049v  3.5  1.5   7.5  
01501*00601*02301  1   1.5   0  
03001*00601*00301  3.5   5  0  
 
1 Representing cases (diagnosis code 1-6) versus controls (diagnosis code 8 and 9).  
 
4.3. Statistical analyses 
 Odds Ratios and p-values were calculated for each allele in both Giant Schnauzer and 
Hovawart, see supplementary table S2A and S2B. The 2x2 Contingency table for DLA-
DRB1*01201DQA1*00101DQB1*00201 in Giant Schnauzer shows an increased risk with an 
odds ratio = 6.0667 and p = 0.015401 for developing CLT. See table 4.  
 
 







Case 26 90 116 
Control 2 42 44 
Total 28 132 160 
 
1 Representing cases (diagnose code 1-6) versus controls (diagnose code 8 and 9).  
 
Risk ratio: 4.931 
Odds ratio: 6.0667 
Χ2: 5.87 




 The aims of this study were to determine the nucleotide sequence of the polymorphic 
exon 2 from three DLA loci i.e. DLA-DRB1, DQA1 and DQB1 and then evaluate the 
association between DLA class II haplotype and the risk for developing CLT. In GS 
the 01201*00101*00201 haplotype shows an increased risk (cases 22.5% versus 
controls 4.5%) with an odds ratio = 6.0667 and p = 0.015401 for developing CLT.  
 In HW the risk haplotype 01201*00401*013017 was present in 45 % (cases 43% 
versus controls 50%) of the total dogs analyzed.  
 The haplotype 01301*00101*00201 also shows an increased risk (cases 15.5% 
versus controls 7.5%) for developing CLT. This indicates that DRB1 is not the genetic 
risk factor. Instead DQA1 and DQB1 could be the genetic factors in the MHC that 
leads to an increased risk for developing the disease. Nucleotide sequence alignment 
of the DQA1*00401 with DQA1*00101 sequences revealed that there is only three 
amino acids differences between the two alleles (Fig. 2). The consensus sequence 
shows where differences are located. The observed amino acid substitutions are non-
conservative. At position X, there is an asparagine to tyrosine change.  Aspargine is 
hydrophilic and thyrosine is hydrophobic. At position X, arginine which has basic 
side-chains is changed for a threonine with hydrophilic side-chains. Finally, at 
position X, methionine is changed for a leucine. Both have hydrophobic side-chains. 
Since this is rather large changes within the hypervariable regions, the antigen binding 
site is likely to be influenced by these amino acid replacements. If the haplotype 
01201*00401*013017 is a risk haplotype, the DQA1 region may not be involved in 
the risk for developing CLT. Instead DRB1 would be the risk factor. But if 
01301*00101*00201 is a risk haplotype DQA1 and DQB1 would be the risk factor.  




In GS, the haplotype 00601*00401*01303 may be protective (cases 8.5% versus 
controls 18%). However, too few samples carrying this haplotype were found and the 
protective association is only suggestive.  
 Inbreeding predisposes for autoimmune diseases. Variation in MHC is important and 
is not maintained in inbred dogs. Therefore, CLT is so common in both Giant 
Schnauzer and Hovawart.  
 A gender difference in Hashimoto's thyroiditis can be shown in humans where 
women have a four to five times higher risk than men to develop the disease. This can 
imply that sex hormones are involved in the development of the human disease.  In 
contrast, our results corroborate the lack of gender effect for CLT risk.16 
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 Recombination has never been observed between DQA1 and DQB1. Therefore one 
can assume the haplotype if the allele at the DRB1 locus and either of DQA1 or DQB1 
is known. Sequencing is therefore not necessary for all three loci.  
 A genome-wide association mapping (GWA) can be performed in future studies to 
identify additional genes contributing to the disease. The dog genome sequence of a 
boxer covering 97% of the genome and approximately 19.300 genes were 
determined.18 Sequence comparison between additional dog breeds resulted in 
identification of ~2.5 million SNPs. From this a 27,000 SNP array has been developed 
for a GWA mapping. To perform this analysis more CLT cases and healthy controls 
are required. Power calculations have indicated that at least samples from 100 
individuals in each category are needed for a disease with 5-fold increased risk i.e. 
similar to that of CLT. At present time, a total of 87 cases and 35 controls have been 
collected.18  
 Obtained information about the disease-causing genes can then be used in selective 
breeding practice in an effort to reduce the frequency of CLT. E.g. a particular MHC 
in combination with other genes can be a disease-causing combination. By not breed 
on these dogs, healthier dogs can be created.  
  These results also give us a better knowledge about MHC, antigen presentation and 
why a particular MHC gives an increased risk for developing CLT.  
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8. Supplementary tables 
 












2.29.001 8 Hovawart 00201 00901 00101 01201 00401 013017 82 23 12 
2.29.002 8 Hovawart 01201 00401 013017 01301 00101 00802 70 22 10 
2.29.003 ? Hovawart 01201 00401 013017 01501 00601 ? 34 31 13 
2.29.004 8 Hovawart 01201 00401 013017 01201 00401 013017 66 25 10 
2.29.005 ? Hovawart 01301 00101 00201 01501 00601 00301 87 27 15 
2.29.006 6 Hovawart 01201 00401 013017 01501 00601 00301 165 20 11 
2.29.008 8 Hovawart 01501 00601 00301 01501 00601 049v 99 16 15 
2.29.013 ? Hovawart 00201 00901 00101 01201 00401 013017 83 34 11 
2.29.017 ? Hovawart 01201 00401 013017 01201 00401 013017 75 28 15 
2.29.018 8 Hovawart 01201 00401 013017 01201 00401 013017 64 13 8 
2.29.019 3 Hovawart 01201 00401 013017 01301 00101 00201 159 102 243 
2.29.020 4 Hovawart 01201 00401 013017 01301 00101 00201 122 21 9 
2.29.021 ? Hovawart 01201 00401 013017 01201 00401 013017 96 27 19 
2.29.022 8 Hovawart 01301 00101 00201 01501 00601 00301 86 16 17 
2.29.025 8 Hovawart 01201 00401 013017 01201 00401 013017 88 25 11 
2.29.026 8 Hovawart 00201 00901 00101 01201 00401 013017 68 16 15 
2.29.027 4 Hovawart 01201 00401 013017 01301 00101 00201 129 22 14 
2.29.028 ? Hovawart 01201 00401 013017 01201 00401 013017 90 27 14 
2.29.029 8 Hovawart 01201 00401 013017 01201 00401 013017 97 20 12 
2.29.031 3 Hovawart 01201 00401 013017 01501 00601 049v 105 16 47 
2.29.032 ? Hovawart 01201 00401 013017 01201 00401 013017 75 32 17 
2.29.035 8 Hovawart 01101 00201 01302 01201 00401 013017 90 25 16 
2.29.036 ? Hovawart 00201 00901 00101 01201 00401 013017 66 30 7 
2.29.037 3 Hovawart 01201 00401 013017 01201 00401 013017 87 6 175 
2.29.038 8 Hovawart 01101 00201 01302 01201 00401 013017 72 22 13 
2.29.041 ? Hovawart 01501 00601 00301 01501 00601 049v 97 30 13 
2.29.044 8 Hovawart 01101 00201 01302 01501 00601 049v 84 23 16 
2.29.045 8 Hovawart 01301 00101 00201 01501 00601 04901 94 19 11 
2.29.059 3 Hovawart 00201 00901 00101 01201 00401 013017 163 25 87 
2.29.081 3 Hovawart 01201 00401 013017 01501 00601 00301 84 19 49 
2.29.082 3 Hovawart 00201 00901 00101 01201 00401 013017 100 0 127 
2.29.087 1 Hovawart 01101 00201 01302 01201 00401 013017 297 0 60 
2.29.089 1 Hovawart 00201 00901 00101 01201 00401 013017 225 39 55 
2.29.105 2 Hovawart 00201 00901 00101 03001 00601 00301 >200 11,2 14 
2.29.106 1 Hovawart 00201 00901 00101 01201 00401 013017 POS 19,7 >200  
2.29.107 1 Hovawart 00201 00901 00101 03001 00601 00301 POS 11,5 780 
2.29.108 3 Hovawart 00201 00901 00101 01501 00601 00301 NEG 11,3 >200  
2.29.109 1 Hovawart 01301 00101 00201 01301 00101 00201 POS 9,9 >200 
2.29.110 3 Hovawart 00201 00901 00101 00201 00901 00101 NEG 7,5 125 
2.29.111 3 Hovawart 01201 00401 013017 01201 00401 013017 NEG 7,3 93 
2.29.112 7 Hovawart 01201 00401 013017 03001 00601 00301 NEG 5,7 35 
2.29.113 3 Hovawart 01301 00101 00201 01301 00101 00201 NEG 21,9 355 
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2.29.114 3 Hovawart 00201 00901 00101 01201 00401 013017 NEG 10,9 >200 
2.29.115 7 Hovawart 00201 00901 00101 01201 00401 013017 NEG 8 31 
2.29.116 6 Hovawart 00201 00901 00101 01201 00401 013017 GRÅ 8,6 29 
2.29.117 3 Hovawart 01201 00401 013017 01301 00101 00201 NEG 8,2 55 
2.29.118 1 Hovawart 00201 00901 00101 01201 00401 013017 225 5,8 55 
2.29.119 7 Hovawart 01201 00401 013017 01301 00101 00201 NEG 7 33 
2.29.120 2 Hovawart 00201 00901 00101 01201 00401 013017 POS 11,5 38 
2.29.121 3 Hovawart 01201 00401 013017 01501 00601 02301 NEG 7,2 40 
2.29.122   Hovawart 01201 00401 013017 01501 00601 049v       
2.45.225 2 Hovawart 01101 00201 01302 01201 00401 013017 254 26 22 
2.45.007 ? Riesen 00601 00401 01303 00601 00401 01303 125 27 17 
2.45.008 4 Riesen 00101 00101 00201 02301 00301 00501 135 19 12 
2.45.009 ? Riesen 02301 00301 00501 02301 00301 00501 117 22 16 
2.45.010 ? Riesen 00101 00101 00201 00601 00401 01303 112 26 15 
2.45.011 6 Riesen 00101 00101 00201 00101 00101 00201 167 25 33 
2.45.013 ? Riesen 00601 00401 01303 01201 00101 00201 103 18 14 
2.45.014 6 Riesen 00101 00101 00201 00601 00401 01303 171 26 17 
2.45.015 8 Riesen 00601 00401 01303 00901 00101 008011 88   15 
2.45.017 ? Riesen 00601 00401 01303 01301 00301 00501 85 34 13 
2.45.018 ? Riesen 00101 00101 00201 00601 00401 01303 129 23 16 
2.45.019 2 Riesen 00101 00101 00201 01501 00601 00301 258 4 14 
2.45.021 ? Riesen 00101 00101 00201 00101 00101 00201 139 19 15 
2.45.022 ? Riesen 01201 00101 00201 01301 00101 00201 143 28 0 
2.45.023 ? Riesen 00101 00101 00201 01201 00101 00201 144 27 15 
2.45.025 ? Riesen 00601 00401 01303 00901 00101 008011 127 22 16 
2.45.026 6 Riesen 00601 00401 01303 01301 00301 00501 171 14 13 
2.45.027 ? Riesen 00601 00401 01303 01201 00101 00201 106 24 0 
2.45.028 ? Riesen 00101 00101 00201 02301 00301 00501 125 29 12 
2.45.030 ? Riesen 00101 00101 00201 02301 00301 00501 100 20 23 
2.45.032 2 Riesen 00101 00101 00201 00101 00101 00201 382 14 8 
2.45.033 ? Riesen 00601 00401 01303 01301 00301 00501 110 15 10 
2.45.034   Riesen 00601 00401 01303 00901 00101 008011       
2.45.035 ? Riesen 01201 00101 00201 01301 00101 00201 96 14 24 
2.45.038 2 Riesen 00601 00401 01303 01301 00301 00501 220 27 21 
2.45.039 4 Riesen 00101 00101 00201 01301 00301 00501 110 29 15 
2.45.040 ? Riesen 00101 00101 00201 00601 00401 01303 65 19 26 
2.45.041 ? Riesen 00101 00101 00201 01301 00301 00501 75 18 24 
2.45.042 8 Riesen 00101 00101 00201 02301 00301 00501 58 20 17 
2.45.043 ? Riesen 00601 00401 01303 00601 00401 01303 130 16 12 
2.45.045 8 Riesen 00601 00401 01303 00601 00401 01303 90 19 15 
2.45.046 8 Riesen 00101 00101 00201 02301 00301 00501 83 14 16 
2.45.047 6 Riesen 01301 00101 00201 01301 00101 00201 173 26 0 
2.45.049 7 Riesen 00101 00101 00201 01201 00101 00201 81 25 36 
2.45.050 ? Riesen 00601 00401 01303 01301 00301 00501 113 21 9 
2.45.052 8 Riesen 00601 00401 01303 00601 00401 01303 63 14 10 
2.45.054   Riesen 02301 00301 00501 02301 00301 00501       
2.45.055 8 Riesen 00101 00101 00201 01301 00301 00501 76   13 
2.45.057 ? Riesen 00601 00401 01303 00601 00401 01303 121 18 20 
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2.45.058 8 Riesen 00601 00401 01303 01301 00301 00501 83 17 0 
2.45.059 4 Riesen 00101 00101 00201 02301 00301 00501 99 21 0 
2.45.062 ? Riesen 00101 00101 00201 01201 00101 00201 57 26 22 
2.45.063 8 Riesen 01301 00101 00201 01301 00301 00501 57 24 12 
2.45.065 4 Riesen 01201 00101 00201 01301 00101 00201 97 6 13 
2.45.068 ? Riesen 00601 00401 01303 01301 00301 00501 119 16 10 
2.45.071 8 Riesen 01301 00101 00201 02301 00301 00501 89 19 11 
2.45.074 8 Riesen 00101 00101 00201 01201 00101 00201 76 11 16 
2.45.075 8 Riesen 00101 00101 00201 00101 00101 00201 70 18 21 
2.45.078 6 Riesen 01201 00101 00201 01301 00301 00501 160 10 14 
2.45.079 ? Riesen 00101 00101 00201 01201 00101 00201 110 18 7 
2.45.080 1 Riesen 00601 00401 01303 01301 00301 00501 255 14 84 
2.45.081 ? Riesen 01301 00301 00501 09401 00401 01303 148 10 10 
2.45.082 8 Riesen 00601 00401 01303 01301 00301 00501 98 13 16 
2.45.084 6 Riesen 01201 00101 00201 01201 00101 00201 165 2 23 
2.45.085 ? Riesen 00101 00101 00201 01201 00101 00201 101 18 20 
2.45.095 ? Riesen 00601 00401 01303 01301 00301 00501 102 14 20 
2.45.097 8 Riesen 01301 00301 00501 02301 00301 00501 57 17 19 
2.45.099 2 Riesen 00601 00401 01303 01301 00101 00201 216 6 21 
2.45.103 ? Riesen 00101 00101 00201 00601 00401 01303 121 20 12 
2.45.104 ? Riesen 00101 00101 00201 00101 00101 00201 101 21 11 
2.45.106 10 Riesen 00101 00101 00201 00601 00401 01303 101 14 26 
2.45.109 4 Riesen 00101 00101 00201 01201 00101 00201 144 5 12 
2.45.110 4 Riesen 00101 00101 00201 00601 00401 01303       
2.45.132   Riesen 01201 00101 00201 01301 00301 00501       
2.45.133 2 Riesen 00101 00101 00201 02301 00301 00501 329 6 14 
2.45.135 3 Riesen 01301 00301 00501 01301 00301 00501 NEG 5,5 88 
2.45.136 ? Riesen 01201 00101 00201 01201 00101 00201 107 21 0 
2.45.137 ? Riesen 01201 00101 00201 01201 00101 00201 110 20 11 
2.45.138 ? Riesen 01201 00101 00201 02301 00301 00501 90 44 13 
2.45.139 3 Riesen 00101 00101 00201 02301 00301 00501 109 10 46 
2.45.140 ? Riesen 01201 00101 00201 01201 00101 00201 106 6 21 
2.45.144 ? Riesen 00601 00401 01303 00601 00401 01303 99 32 12 
2.45.150 2 Riesen 00101 00101 00201 01301 00301 00501 381 22 32 
2.45.153 ? Riesen 00101 00101 00201 01301 00301 00501 72 29 0 
2.45.161 ? Riesen 01301 00301 00501 01501 00601 00301 64 26 11 
2.45.164 2 Riesen 00101 00101 00201 01201 00101 00201 389 16 30 
2.45.167 ? Riesen 00101 00101 00201 00101 00101 00201 120 17 12 
2.45.169 4 Riesen 00101 00101 00201 01201 00101 00201 112 20 9 
2.45.171 1 Riesen 01301 00301 00501 01301 00301 00501 POS 4,7 123 
2.45.173 ? Riesen 01301 00301 00501 01501 00601 00301 93 26 9 
2.45.175 ? Riesen 00601 00401 01303 02301 00301 00501 116 19 15 
2.45.179 ? Riesen 00601 00401 01303 01201 00101 00201 88 40 10 
2.45.180 ? Riesen 00601 00401 01303 01301 00301 00501 86 18 26 
2.45.183 ? Riesen 00101 00101 00201 01301 00101 00201 145 13 17 
2.45.186 10 Riesen 00101 00101 00201 01301 00101 00201 101 10 26 
2.45.189 6 Riesen 01201 00101 00201 02301 00301 00501 167 15 11 
2.45.196 6 Riesen 01201 00101 00201 01201 00101 00201 151 21 0 
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2.45.197 ? Riesen 01301 00101 00201 01301 00301 00501 100 13 20 
2.45.206 2 Riesen 01201 00101 00201 01201 00101 00201 1377 34 17 
2.45.207 ? Riesen 00101 00101 00201 00601 00401 01303 64 46 14 
2.45.214 ? Riesen 00101 00101 00201 01301 00301 00501 101 28 10 
2.45.215 ? Riesen 01301 00301 00501 01501 00601 00301 105 34 9 
2.45.217 1 Riesen 00101 00101 00201 01301 00301 00501 302 5 56 
2.45.218 2 Riesen 01201 00101 00201 01201 00101 00201 449 15 31 
2.45.221 ? Riesen 01301 00301 00501 01301 00301 00501 122 22 19 
2.45.222 3 Riesen 00601 00401 01303 01301 00301 00501 81 10 41 
2.45.223 7 Riesen 00101 00101 00201 01301 00301 00501 52 30 36 
2.45.224 ? Riesen 00101 00101 00201 00601 00401 01303 130 17 10 
2.45.227 1 Riesen 01201 00101 00201 01301 00301 00501 1436 5 54 
2.45.228 ? Riesen 00101 00101 00201 01301 00301 00501 121 25 21 
2.45.229 2 Riesen 00101 00101 00201 01301 00301 00501 NEG 2,4 49 
2.45.235 10 Riesen 00101 00101 00201 01501 00601 00301 131 16 22 
2.45.239 6 Riesen 01301 00301 00501 01501 00601 00301 152 20 0 
2.45.241 2 Riesen 01201 00101 00201 01201 00101 00201 200 16 0 
2.45.244 2 Riesen 00101 00101 00201 00101 00101 00201 592 19 0 
2.45.246 ? Riesen 00101 00101 00201 01301 00101 00201 73 28 18 
2.45.247 ? Riesen 00101 00101 00201 00101 00101 00201 130 13 16 
2.45.248   Riesen 00101 00101 00201 00601 00401 01303       
2.45.249 ? Riesen 00101 00101 00201 00101 00101 00201 107 30 8 
2.45.250 1 Riesen 00101 00101 00201 00601 00401 01303 1106 2 58 
2.45.251 ? Riesen 00101 00101 00201 00601 00401 01303 108 20 12 
2.45.252 ? Riesen 00101 00101 00201 00601 00401 01303 101 18 8 
2.45.253 9 Riesen 00101 00101 00201 00101 00101 00201 81 24 11 
2.45.254 9 Riesen 00101 00101 00201 00101 00101 00201 54 20 12 
2.45.256 9 Riesen 01301 00301 00501 01501 00601 00301 91 4 15 
2.45.265 9 Riesen 00601 00401 01303 00901 00101 008011 97 23 17 
2.45.267 7 Riesen 00101 00101 00201 00101 00101 00201 89 28 38 
2.45.271 9 Riesen 00101 00101 00201 00101 00101 00201 92 23 13 
2.45.272 ? Riesen 00101 00101 00201 00601 00401 01303 82 26 13 
2.45.288 6 Riesen 01201 00101 00201 02301 00301 00501 GRÅ 7 26 
2.45.289 2 Riesen 00101 00101 00201 01301 00101 00201 POS 2,7 <14 
2.45.290 7 Riesen 01301 00301 00501 01301 00301 00501 NEG 8 32 
2.45.291 2 Riesen 00101 00101 00201 02301 00301 00501 POS 5 22 
2.45.292 8 Riesen 01201 00101 00201 02301 00301 00501 NEG 11,6 <14 
2.45.293 ? Riesen 00601 00401 01303 00601 00401 01303 NEG 7,3 <14 
2.45.294 1 Riesen 01301 00101 00201 01301 00301 00501 POS 14 163 
2.45.295 ? Riesen 00601 00401 01303 01201 00101 00201 NEG 5,1 <14 
2.45.296 ? Riesen 00101 00101 00201 01301 00301 00501 NEG 5,9 24 
2.45.297 3 Riesen 01201 00101 00201 02301 00301 00501 GRÅ 4,6 49 
2.45.298 1 Riesen 00101 00101 00201 01201 00101 00201 POS 1,4 45 
2.45.299 ? Riesen 00101 00101 00201 01301 00101 00201 NEG 20,7 <14 
2.45.300 8 Riesen 01301 00301 00501 02301 00301 00501 NEG 8 <14 
2.45.301 9 Riesen 00101 00101 00201 02301 00301 00501 NEG 16,5 <14 
2.45.302 3 Riesen 00101 00101 00201 01301 00301 00501 NEG 2,4 49 
2.45.303 ? Riesen 00601 00401 01303 01301 ? ? NEG 2,8 19 
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2.45.304 9 Riesen 00101 00101 00201 01301 00301 00501 NEG 12,5 17 
2.45.305 6 Riesen 01201 00101 00201 01301 00101 00201 GRÅ 6,4 27 
2.45.306 2 Riesen 01301 00101 00201 01301 00301 00501 POS 6,3 19 
2.45.307 ? Riesen 00101 00101 00201 01201 00101 00201 NEG 4,9 19 
2.45.308 ? Riesen 01301 00101 00201 01301 00301 00501 NEG 4 23 
2.45.309 ? Riesen 00101 00101 00201 01201 00101 00201 NEG 7,7 26 
2.45.310 2 Riesen 01301 00101 00201 01301 00301 00501 POS 5,5 29 
2.45.311 ? Riesen 01201 00101 00201 01301 00301 00501 NEG 6,3 20 
2.45.312 6 Riesen 01201 00101 00201 01301 00301 00501 GRÅ 8,5 23 
2.45.313 ? Riesen 01201 00101 00201 01301 00301 00501 NEG 5,4 20 
2.45.314 3 Riesen 01301 00301 00501 01301 00301 00501 NEG 5,5 88 
2.45.315 7 Riesen 01201 00101 00201 01301 00101 00201 NEG 3,7 38 
2.45.316 3 Riesen 01201 00101 00201 01301 00301 00501 NEG 4,6 83 
2.45.317 3 Riesen 00101 00101 00201 01201 00101 00201 NEG 4,7 40 
2.45.318 1 Riesen 01301 00301 00501 01301 00301 00501 POS 4,7 123 
2.45.319 3 Riesen 00101 00101 00201 00601 00401 01303   10,2 54 
2.45.320 3 Riesen 00601 00401 01303 01301 00101 00201   24,9 >200 






































Case 31 85 116 
Control 14 30 44 
Total 45 115 160 
Risk ratio: 0.8399 
Odds ratio: 0.7815 
Χ2: 0.2 







Case 10 106 116 
Control 8 36 44 
Total 18 142 160 
Risk ratio: 0.4741 
Odds ratio: 0.4245 
Χ2: - 







Case 0 116 116 
Control 2 42 44 
Total 2 158 160 
Risk ratio: 0 
Odds ratio: 0 
Χ2: - 







Case 26 90 116 
Control 2 42 44 
Total 28 132 160 
Risk ratio: 4.931 
Odds ratio: 6.0667 
Χ2: 5.87 








Case 11 105 116 
Control 2 42 44 
Total 13 147 160 
Risk ratio: 2.0862 
Odds ratio: 2.2 
Χ2: - 







Case 28 88 116 
Control 8 36 44 
Total 36 124 160 
Risk ratio: 1.3276 
Odds ratio: 1.4318 
Χ2: 0.35 







Case 8 108 116 
Control 7 37 44 
Total 15 145 160 
Risk ratio: 0.4335 
Odds ratio: 0.3915 
Χ2: - 







Case 0 116 116 
Control 0 44 44 
Total 0 160 160 
Risk ratio: 0 
Odds ratio: 0 
Χ2: - 








Case 0 116 116 
Control 0 44 44 
Total 0 160 160 
Risk ratio: 0 
Odds ratio: 0 
Χ2: - 







Case 2 114 116 
Control 1 43 44 
Total 3 157 160 
Risk ratio: 0.7586 
Odds ratio: 0.7544 
Χ2: - 
p = - 
 
 







Case 14 44 58 
Control 2 24 26 
Total 16 68 84 
Risk ratio: 3.1379 
Odds ratio: 3.8182 
Χ2: - 







Case 2 56 58 
Control 3 23 26 
Total 5 79 84 
Risk ratio: 0.2989 
Odds ratio: 0.2738 
Χ2: - 








Case 25 33 58 
Control 13 13 26 
Total 38 46 84 
Risk ratio: 0.8621 
Odds ratio: 0.7576 
Χ2: 0.12 







Case 9 49 58 
Control 2 24 26 
Total 11 73 84 
Risk ratio: 2.0172 
Odds ratio: 2.2041 
Χ2: - 







Case 0 58 58 
Control 1 25 26 
Total 1 83 84 
Risk ratio: 0 
Odds ratio: 0 
Χ2: - 







Case 3 55 58 
Control 2 24 26 
Total 5 79 84 
Risk ratio: 0.6724 
Odds ratio: 0.6545 
Χ2: - 








Case 0 58 58 
Control 1 25 26 
Total 1 83 84 
Risk ratio: 0 
Odds ratio: 0 
Χ2: - 
p = - 
 





Case 1 57 58 
Control 2 24 26 
Total 3 81 84 
Risk ratio: 0.2241 
Odds ratio: 0.2105 
Χ2: 0 







Case 1 57 58 
Control 0 26 26 
Total 1 83 84 
Risk ratio: ∞ 
Odds ratio: ∞ 
Χ2: - 







Case 3 55 58 
Control 0 26 26 
Total 3 81 84 
Risk ratio: ∞ 
Odds ratio: ∞ 
Χ2: - 
p = - 
 
 
